Cullinan Therapeutics, Inc. · NASDAQ:CGEM
Cullinan Therapeutics — Merger or Acquisition (June 2025)
17 slides from Cullinan Therapeutics's merger presentation, Jun 4, 2025
Slide 1: Licensing of velinotamig (BCMAxCD3) from Genrix Bio
June 2025 Cullinan Therapeutics Licensing of velinotamig (BCMAxCD3) from Genrix Bio Exhibit 99.2
Slide 2: Important Notice and Disclaimers
Important Notice and Disclaimers This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Cullinan’s beliefs and expectat
Slide 3: Agenda
Agenda Introduction Nadim Ahmed BCMA & Velinotamig Overview Jeff Jones Deal Terms & Financial Context Mary Kay Fenton Strategic Perspective & Next Steps Nadim Ahmed Q&A Nadim Ahmed Chief Executive Officer Jeff Jones, MD, MBA Chief Medical Officer Mary Kay Fenton Chief Financial Officer 3 © CULLINAN
Slide 4: Cullinan Therapeutics: Our Mission
CULLINAN THERAPEUTICS Our Mission: Create new standards of care for patients Cullinan Therapeutics is entering into an agreement with Genrix Bio for a global (ex-Greater China*), all indication, exclusive license agreement for velinotimag. Velinotamig is a BCMAxCD3 bispecific T cell engager (TCE) wi
Slide 5: Combined ~41.6M patients globally
Combined ~41.6M patients globally Source: SLE: Tian J, Zhang D, Yao X, Huang Y, Lu Q. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis. Published online October 14, 2022. RA: Rheumatoid arthritis: Key Facts. WHO. Published on
Slide 6: Plasma cell depletion may be important for disease modification of autoimmune diseases
© CULLINAN THERAPEUTICS, INC. ALL RIGHTS RESERVED. Plasma cell depletion may be important for disease modification of autoimmune diseases driven by long-lived plasma cells BCMA B cell dysfunction is central to the pathogenesis of many autoimmune diseases, and broadly and deeply depleting these cells
Slide 7: Established MOA and validated target: teclistamab data in autoimmune diseases
Established MOA and validated target: clinical data for teclistamab, a BCMAxCD3 bispecific T cell engager, in autoimmune diseases SLE = Systemic Lupus Erythematosus; RA = Rheumatoid Arthritis; SjD = Sjögren’s Disease; IIM = Idiopathic Inflammatory Myositis; SSc = Systemic Sclerosis Hagen M et al. NE
Slide 8: Velinotamig: a highly selective, differentiated molecule
VELINOTAMIG BISPECIFIC BCMAXCD3 T CELL ENGAGER VELINOTAMIG A HIGHLY SELECTIVE, DIFFERENTIATED MOLECULE Binds to the BCMA and CD3 antigens, redirecting cytotoxic T cells to target BCMA-expressing cells High affinity for BCMA and lower affinity for CD3: affinity for BCMA is two orders of magnitude hig
Slide 9: Velinotamig current clinical development status in China
Velinotamig current clinical development status in China GR1803-001: A (follow-up) completed Phase 1 study in patients with relapsed/refractory multiple myeloma GR1803-002: A Phase 2 pivotal study in patients with relapsed/refractory multiple myeloma GR1803-003: A Phase 2 pivotal study in patients w
Slide 10: Agreement builds upon accumulated data, leveraging Genrix Bio's expertise and KOL network
Agreement builds upon accumulated data, leveraging Genrix Bio’s established expertise and KOL network to accelerate clinical development Genrix Bio has an existing network of leading autoimmune clinical investigators in China, allowing for rapid study start-up and patient accrual for the planned Pha
Slide 11: Velinotamig efficacy in relapsed/refractory multiple myeloma: Phase 1 results
Velinotamig has demonstrated meaningful efficacy in late-line patients with relapsed/refractory multiple myeloma: Phase 1 results at RP2D target dose Approved moleculesb (in U.S. and or EU) Velinotamiga (n=48) Elranatamab1,2 (n=97) Teclistamab3,4,5 (n=110) Linvoseltamab6 (n=117) ORR (sCR + CR + VGPR
Slide 12: Overview of velinotamig safety data at RP2D target dose
Overview of velinotamig safety data at RP2D target dose Any grade ≥Grade3 Velinotamig (n=48)* Cytokine release syndrome 89.6% 6.3% Infection 81.3% 50.0% ICANS 0% 0% Neutrophil count decreased 89.6% 64.6% Platelet count decreased 79.2% 39.6% White blood cell count decreased 89.6% 35.4% Lymphocyte cou
Slide 13: Enthusiasm for CLN-978 provides momentum for velinotamig development
Enthusiasm for CLN-978 from global network of investigators, leading KOLs and patient advocacy groups provides momentum for velinotamig development VELINOTAMIG AUTOIMMUNE DISEASES Plans to initiate a Phase 1 trial Aim: Evaluate the safety, PK, PD, and potential effectiveness of velinotamig CLN-978 R
Slide 14: Deal provides favorable upfront economics for Cullinan
Deal provides favorable upfront economics for Cullinan for an asset with meaningful efficacy and safety data and best-in-class potential Coupled with refining our oncology pipeline, Cullinan can reiterate existing guidance to have cash resources into 2028 based on current operating plan Upfront lic
Slide 15: Next steps: rapid initiation of global regulatory and clinical development plans
Next steps: Focused on rapid initiation of global regulatory and clinical development plans Execute parallel development for CLN-978 and velinotimag across both B-cell and plasma cell mediated autoimmune diseases Genrix Bio initiates Phase 1 study, characterizing the safety and tolerability profile
Slide 16: Velinotamig agreement illustrates strategy of aligning target with best modality
Velinotamig agreement illustrates strategy of aligning the right target with the best modality while utilizing our core expertise in T cell engagers Leveraging our extensive investigator and KOL network, we will continue to be a leader in developing and advancing T cell engagers in the clinic in aut
Slide 17: Q&A
CULLINAN THERAPEUTICS Q&A Nadim Ahmed Chief Executive Officer Jeff Jones, MD, MBA Chief Medical Officer Mary Kay Fenton Chief Financial Officer © CULLINAN THERAPEUTICS, INC. ALL RIGHTS RESERVED.
Cullinan Therapeutics — Merger or Acquisition (June 2025) on 6ix